ECU Health Medical Center is expanding advanced heart care with state-of-the-art technology for transcatheter tricuspid valve ...

Anteris Technologies Global Corp.’s AVR share price has dipped by 5.20%, which has investors questioning if this is right ...

Edwards stock shot higher Thursday after the medtech player said tariffs are likely to have little impact in 2025.

The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

Two state-of-the-art new technologies for transcatheter tricuspid valve replacements is expanding advanced heart care with ...

Piper Sandler upgraded Edwards Lifesciences (EW) to Overweight from Neutral with a price target of $80, up from $73. The firm sees a “better ...

Edwards Lifesciences raised its 2025 sales forecast on Wednesday after a quarterly beat, driven by robust demand for its artificial heart valves and other medical equipment. The company has revised ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights. Q1 ...

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients with severe aortic stenosis (AS), a valvular heart condition that can be ...

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

Vivasure hope to find room in a competitive market with its surtureless implant that is absorbed 180 days after vessel ...